Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 2/20 | 0.38 |
| ▸ | EP300 | Q09472 | 4/20 | 0.35 |
| ▸ | TYR | P14679 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2351474 | 0.76 | TLR8 (0.38) | ADORA2B | |
| SCHEMBL21695515 | 0.73 | KAT2B (0.40) | EP300 | |
| SCHEMBL2346346 | 0.72 | ADORA2B (0.41) | ADORA2B | |
| SCHEMBL591865 | 0.71 | DRD2 (0.44) | ADORA2B | |
| SCHEMBL2349675 | 0.71 | MAPT (0.37) | ADORA2BEP300 | |
| SCHEMBL3567954 | 0.71 | TLR8 (0.46) | — | |
| SCHEMBL12154069 | 0.70 | KDM4E (0.32) | — | |
| SCHEMBL2349445 | 0.69 | ADORA2B (0.51) | ADORA2BMAPK1RXFP1 | |
| SCHEMBL591657 | 0.68 | TK1 (0.56) | MAPK1 | |
| SCHEMBL2497466 | 0.67 | TK2 (0.56) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006103342-A2 | INDANYL-PIPERAZINE DERIVATIVES, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | LES LABORATOIRES SERVIER (FR) | 2006-10-05 | — | — | WO | claimed |
| US-8008488-B2 | Pyrimidin-2-one compounds and their use as dopamine D3 receptor ligands | ABBOTT GMBH & CO. KG (DE) | 2011-08-30 | — | — | US | disclosed |
| EP-1601659-B1 | PYRIMIDIN-2-ONE COMPOUNDS AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | ABBOTT GMBH & CO KG (DE) | 2008-01-16 | — | — | EP | disclosed |
| US-20060235004-A1 | Pyrimidin-2-one compounds and their use as dopamine d3 receptor ligands | ABBOT GMBH & CO. KG (DE) | 2006-10-19 | — | — | US | disclosed |
| EP-1601659-A1 | PYRIMIDIN-2-ONE COMPOUNDS AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | Abbott GmbH & Co. KG (DE) | 2005-12-07 | — | — | EP | disclosed |
| WO-2004080981-A1 | PYRIMIDIN-2-ONE COMPOUNDS AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | ABBOTT GMBH & CO. KG (DE) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235004-A1 | Pyrimidin-2-one compounds and their use as dopamine d3 receptor ligands | ADRB3, DRD3, OPRL1 | ADORA2B 187/4885EP300 3162/4885TYR 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.